Glytec today unveiled the newest version of its Glucommander insulin dosing software that enables best practice, personalized care. The Glucommander platform helps to streamline workflows, improve outcomes and support electronic health record (EHR) systems. Waltham, Massachusetts-based Glytec says it closely follows the next evolution of GlucoMetrics released this past spring. GlucoMetrics provides new insights and […]
Patient Monitoring
Abbott FreeStyle Libre 3 reader is now available, covered by Medicare
Abbott (NYSE:ABT) has made its FreeStyle Libre 3 reader available in the U.S., enabling people on Medicare to access the system. The FreeStyle Libre 3 reader pairs with the company’s latest continuous glucose monitor (CGM) sensor, cleared by the FDA last year. The addressable market for the sensor keeps growing, with massive coverage expansions all […]
Dexcom more than doubles profits on 25% sales growth in Q2
Dexcom (Nasdaq:DXCM) shares are up today on second-quarter results that topped the consensus forecast. Shares of DXCM rose 2.3% at $132.35 apiece after the market closed yesterday. By the next afternoon, DXCM shares were up more than 4% to $134.71 apiece. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device […]
Report: Insulet prevails over Medtrum in France patent spat
According to a report in Europe, a Paris court found that Medtrum’s latest insulin pumps infringe an Insulet (Nasdaq:PODD) patent. JUVE Patent reported that earlier this month, the Judicial Court of Paris declared the infringement. The court found that Medtrum’s newest pump base and patch reservoir models violate the EP2438957B1 patent from Insulet. In declaring […]
Know Labs has more positive data for its non-invasive glucose monitor
Know Labs (NYSE:KNW) today announced results from a new study that further demonstrate the accuracy of its Bio-RFID sensor technology. Last month, the company unveiled the prototype for its proprietary non-invasive sensor technology. Its proprietary Bio-RFID technology uses spectroscopy to direct electromagnetic energy through a substance or material. Through this, it can capture a unique molecular signature. The […]
Feasibility study backs Glucotrack implantable CGM
Glucotrack (Nasdaq:GCK) announced today that it completed a feasibility study for its implantable continuous glucose monitor (CGM). Rutherford, New Jersey-based Glucotrack designed its CGM for patients with type 1 and type 2 insulin-dependent diabetes. The company said late last year that it planned to expand its product pipeline with an R&D program. The program centers around developing […]
Abbott Diabetes business booms in Q2, company set to submit new sensor in U.S. this year
Abbott (NYSE:ABT) today shared a number of positive updates on its Diabetes business as part of its second-quarter earnings report. The medtech giant’s Diabetes unit brought in sales of $1.4 billion in the quarter, marking 19.4% growth year-over-year. Its FreeStyle Libre continuous glucose monitors (CGMs) continue to drive growth as CEO Robert Ford projected earlier […]
Ascensia Diabetes Care inks deal to integrate blood glucose monitors in point-of-care testing
Avricore Health and Ascensia Diabetes Care announced a partnership to integrate blood glucose monitoring into point-of-care testing. The deal aims to integrate the Contour Next-Gen and Contour Next One BGM systems into Avricore’s HealthTab PCOT platform. Both companies have the objective of supporting patients and pharmacists in Canada to better manage diabetes. The companies believe […]
Better Therapeutics wins FDA nod for type 2 diabetes digital therapeutic
Better Therapeutics (Nasdaq:BTTX) announced that the FDA authorized its AspyreRx prescription digital therapeutic for diabetes. AspyreRx, formerly BT-001, provides cognitive behavioral therapy to patients 18 years or older with type 2 diabetes. The prescription-only digital therapeutic (PDT) underwent review through the FDA de novo pathway. The company submitted an FDA de novo request in September 2022 for […]
Medicare now covers new Medtronic MiniMed 780G automated insulin pump
Medtronic (NYSE:MDT) announced today that Medicare now covers its new MiniMed 780G system with the Guardian 4 sensor. Coverage for the recently FDA-approved automated insulin delivery system extends to all eligible Medicare and Medicare Advantage beneficiaries. Medtronic intends to begin processing orders immediately. The company plans to start shipments to eligible recipients with type 1 […]